Reduced fluence photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor antibody for age-related macular degeneration.

Reduced fluence photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor antibody for age-related macular degeneration. - RFPDT combined with anti-VEGF antibody for AMD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004562

Enrollment

Registered

2010-11-15

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration

Interventions

RFPDT anti-VEGFantibody

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Finding choroidal vascular abnormalities with AMD, and vision loss.

Exclusion criteria

Exclusion criteria: the patient without exudative changes in fundus.

Design outcomes

Primary

Measure	Time frame
vision acuity, disapearment of neovascularization.	—

Countries

Japan

Contacts

Public ContactShion Hayashi

Yamagata University faculty of Medicine Department of Ophthalmology

shion_haneda055@hotmail.com+81-23-628-5374

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026